Premium
Prevalence of Epstein–Barr virus in oral squamous cell carcinoma
Author(s) -
Kobayashi Ieyoshi,
Shima Kaori,
Saito Ichiro,
Kiyoshima Tamotsu,
Matsuo Kou,
Ozeki Satoru,
Ohishi Masamichi,
Sakai Hidetaka
Publication year - 1999
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/(sici)1096-9896(199909)189:1<34::aid-path391>3.0.co;2-4
Subject(s) - epstein–barr virus , in situ hybridization , polymerase chain reaction , virus , southern blot , biology , carcinoma , pathology , epstein–barr virus infection , dot blot , herpesviridae , virology , medicine , viral disease , gene , messenger rna , biochemistry
Forty‐six samples of oral squamous cell carcinoma (OSCC) were evaluated for the prevalence of Epstein–Barr virus (EBV) infection by the polymerase chain reaction (PCR), Southern blot hybridization, and in situ hybridization (ISH). EBV DNA was detected in 7 (15·2 per cent) out of 46 samples by a combination of PCR and Southern blot hybridization methods. All seven positive samples showed well‐differentiated carcinoma, thus suggesting a possible relationship between EBV infection and the degree of differentiation of carcinoma tissue. Latent infection membrane protein 1 (LMP1) was detected immunohistochemically in six of the EBV‐positive OSCCs. However, no signal of the EBV‐encoded small RNA (EBER)‐1 was demonstrated by the ISH method. No significant relationship was observed between EBV infection and lymph node metastasis. A follow‐up study (range from 4·4 to 79 months; mean 34·9 months) showed no recurrence or death to occur in the EBV‐positive patients, which thus suggested a good prognosis for EBV‐positive OSCC patients. Copyright © 1999 John Wiley & Sons, Ltd.